New oral anticoagulants targeting thrombin or Factor Xa offer a promising alternative to VKAs for long-term anticoagulation without the need for routine monitoring.
No takes yet. Share an insight, caveat, or question.
Should not yet change practice; leaves open need for RCTs confirming long-term safety versus VKAs.
Jeffrey I. Weitz (2010) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: